Results 171 to 180 of about 242,137 (307)

Characteristics of blood lipid and metabolic indicators in subclinical hypothyroidism patients: a retrospective study [PDF]

Li Zhu, Xiaohong Jiang
openalex   +1 more source

Therapeutic recommendations in hypothyroidism

, 2020
Nicoleta Mirela Blebea, Laura Bucur
openalex   +1 more source

Epicardial Adipose Tissue Increased in Patients with Newly Diagnosed Subclinical Hypothyroidism [PDF]

, 2012
Levent Korkmaz, Sinan Şahin, Ali Rıza Akyüz, Murat Zıyrek, İnan Anaforoğlu, Mustafa Köse, Hakan Erkan, Mustafa Tarık Ağaç, Zeydin Acar   +8 more
openalex   +1 more source

Frontotemporal dementia: Clinical aspects, genetics, and neuropathology of a family with a C9ORF72 expansion in Argentina

Brain Pathology, EarlyView.
Immunohistochemistry for TDP‐43: (A)—Dentate gyrus; (B)—Temporal lobe. Abstract Frontotemporal dementia (FTD) is the second most common cause of early‐onset dementia, typically manifesting before the age of 65, with a mean onset at 58 years. FTD may encompass a spectrum of neurodegenerative disorders resulting from frontotemporal lobar degeneration ...
Karen Daniela Román, Carolina Agata Ardohain, Ezequiel I. Surace, Mónica Beatriz Mezmezian, Alejandro Levy, Alice Baez Lovera, Carlos Turizo, Marcos G. Sorbara, María M. Esnaola y Rojas, Gastón H. Graviotto, Gustavo Sevlever, Ricardo F. Allegri, Cecilia M. Serrano, Nahuel Magrath Guimet   +13 more
wiley   +1 more source

Multi-omics analysis of the potential association between metabolic features of hypothyroidism in the first half of pregnancy and Th17/Treg balance. [PDF]

Front Immunol
Wang Y, Xu Y, Li J, Zhang M, Sun Z, Zhang C, Lin P.   +6 more
europepmc   +1 more source

Hypothyroidism [PDF]

, 2009
P. M. Atapattu
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Integrative multi-omics analyses identify key genes and elucidate bidirectional regulatory mechanisms in thyroid dysfunction. [PDF]

PLoS One
Hu Y, Hu H, Xu L, Tang X, Wang C, Lian Z, Xie C, Xie Z, Wang Q.   +8 more
europepmc   +1 more source

A Cross-Sectional Study on the Prevalence of Subclinical Hypothyroidism in Metabolic Syndrome Patients at a Tertiary Care Hospital [PDF]

Gaurav Lakhani, Parth Patel, Tinkal Patel   +2 more
openalex   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source